𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

✍ Scribed by Manousos M. Konstadoulakis; Pantelis T. Antonakis; Basil G. Tsibloulis; George P. Stathopoulos; Andreas P. Manouras; Despoina B. Mylonaki; Basil X. Golematis

Publisher
Springer
Year
2001
Tongue
English
Weight
72 KB
Volume
48
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of amonafide in advanced
Phase II study of amonafide in advanced pancreatic adenocarcinoma
✍ Kaye Linke; Richard Pazdur; James L. Abbruzzese; Jaffer A. Ajani; Rodger Winn; J πŸ“‚ Article πŸ“… 1991 πŸ› Springer US 🌐 English βš– 262 KB

To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. The starting dose was 400 mg/m 2 administered daily over 1 hr for 5 consecutive days repeated every 3 weeks. Be

Results of a 2-arm Phase II study of 9-n
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas
✍ Shreyaskumar R. Patel; Jennifer Beach; Nicholas Papadopoulos; M. Andrew Burgess; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 3 views

## Abstract ## BACKGROUND The authors conducted a 2‐arm Phase II trial of 9‐nitrocamptothecin (9‐NC), an oral topoisomerase I inhibitor, to define response rates in patients with gastrointestinal (GI) leiomyosarcomas and other soft‐tissue sarcomas (STS). ## METHODS Patients were required to prov